| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 63323-0193-55 | 63323-0193 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Apr 1, 2009 | In Use | |
| 68083-0381-01 | 68083-0381 | Irinotecan hydrochloide | Irinotecan hydrochloide | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov 18, 2019 | In Use | |
| 67979-0001-02 | 67979-0001 | Valrubicin | Valstar | 40.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravesical | Oct 1, 1998 | Oct 17, 2017 | In Use |
| 00310-1349-30 | 00310-1349 | Osimertinib | Tagrisso | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 13, 2015 | In Use | |
| 00703-4412-11 | 00703-4412 | Vincristine Sulfate | Vincasar PFS | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | May 1, 2000 | Jul 31, 2022 | No Longer Used |
| 00310-7820-30 | 00310-7820 | Vandetanib | Caprelsa | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Oral | Jul 25, 2011 | May 31, 2020 | No Longer Used |
| 59676-0966-02 | 59676-0966 | doxorubicin hydrochloride | Doxorubicin Hydrochloride liposome | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jun 26, 2017 | Oct 31, 2020 | No Longer Used |
| 00069-0358-20 | 00069-0358 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug 19, 2024 | In Use | |
| 49884-0128-91 | 49884-0128 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Nov 29, 2022 | In Use | |
| 71288-0102-10 | 71288-0102 | Bendamustine HCl | Bendamustine | 25.0 mg/5mL | Chemotherapy | Alkylating Agent | Purine analog | Intravenous | Jun 5, 2023 | In Use | |
| 00069-1235-30 | 00069-1235 | Talazoparib | Talzenna | 0.35 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 21, 2023 | Oct 31, 2025 | In Use |
| 82009-0086-90 | 82009-0086 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 1, 2023 | In Use | |
| 70710-1656-01 | 70710-1656 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 11, 2023 | In Use | |
| 70771-1693-01 | 70771-1693 | Pemetrexed disodium | Pemetrexed | 1000.0 mg/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 26, 2022 | In Use | |
| 70860-0214-61 | 70860-0214 | Melphalan hydrochloride | Melphalan hydrochloride | 50.0 mg/10ml | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jul 30, 2019 | Oct 31, 2025 | In Use |
| 00781-3255-94 | 00781-3255 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Oct 31, 2014 | In Use | |
| 70710-1411-01 | 70710-1411 | BORTEZOMIB | BORTEZOMIB | 1.0 mg/mL | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
| 63020-0210-21 | 63020-0210 | Fruquintinib | Fruzaqla | 1.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov 8, 2023 | In Use | |
| 63759-3049-01 | 63759-3049 | Pemetrexed disodium | Pemetrexed | 500.0 mg/50mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jan 1, 2024 | In Use | |
| 62559-0924-51 | 62559-0924 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 16, 2020 | Feb 28, 2023 | No Longer Used |
| 00085-1425-01 | 00085-1425 | Temozolomide | Temodar | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | Oct 22, 2014 | In Use |
| 65162-0802-14 | 65162-0802 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 3, 2015 | In Use | |
| 55390-0215-01 | 55390-0215 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 15, 2007 | Sep 30, 2011 | No Longer Used | |
| 70709-0151-20 | 70709-0151 | Dasatinib | PHYRAGO | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 22, 2025 | In Use | |
| 31722-0296-90 | 31722-0296 | IMATINIB MESYLATE | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 14, 2025 | In Use |
Found 11888 results — Export these results
Home